Hepatic Encephalopathy & Acute Liver Failure

Hepatic Encephalopathy — Classification & Pathophysiology

Definition

Hepatic Encephalopathy (HE) is a spectrum of neuropsychiatric abnormalities occurring in patients with liver failure — either acute or chronic (cirrhosis) — or portosystemic shunting, after exclusion of other causes of brain dysfunction.

Neuropsychiatric Reversible (mostly) Life-threatening in Grade 3–4 Treatable precipitants

Pathophysiology

Ammonia Hypothesis (Primary)

Gut bacteria break down nitrogenous substrates (protein, blood) → ammonia (NH3)
Healthy liver converts NH3 to urea (urea cycle) — bypassed in liver failure / portosystemic shunts
NH3 crosses blood–brain barrier → astrocyte swelling (glutamine accumulation via glutamine synthetase)
Cerebral oedema, raised intracranial pressure (especially acute liver failure)
Glutamate/glutamine imbalance → impaired neurotransmission

Additional Mechanisms

Neuroinflammation: Circulating inflammatory mediators (LPS, cytokines) synergise with ammonia to worsen encephalopathy — infection dramatically worsens HE
Manganese deposition: Portal hypertension → manganese bypasses liver → deposits in basal ganglia → T1 hyperintensity on MRI, extrapyramidal features
GABA-ergic tone: Increased inhibitory GABA activity contributes to sedation
Zinc deficiency: Zinc is cofactor for urea cycle enzymes — common in cirrhosis

West Haven Criteria (WHC) — Grading Scale

Grade	Consciousness	Intellect / Behaviour	Neurological Signs	Nursing Priority
MHE	Normal	Psychometric tests abnormal only — no clinical signs	None clinically evident	Driving advice, QoL support, rifaximin consider
Grade 1	Mild confusion, altered sleep–wake cycle (insomnia / hypersomnia)	Shortened attention span, mild mood change, anxiety or euphoria	Asterixis may be present (mild)	Lactulose, close monitoring, safety assessment
Grade 2	Lethargy, moderate confusion	Disorientation to time, obvious personality change, inappropriate behaviour	Asterixis prominent (flapping tremor), dysarthria, ataxia	Bed rails, aspiration risk, 2-hourly neuro obs
Grade 3	Somnolent but rousable to voice/painful stimulus	Gross disorientation, incomprehensible speech	Asterixis present (if rousable), hyperreflexia, clonus	Airway adjunct, HDU/ICU escalation, suction at bedside
Grade 4	Coma — unresponsive to all stimuli	No purposeful response	Absent asterixis (cannot be tested), decerebrate/decorticate posturing	ICU, intubation assess, ICP monitoring in ALF

⚠

Asterixis (Flapping Tremor): Ask patient to extend arms with wrists dorsiflexed. Positive = rhythmic flapping jerks at wrist. Absent in Grade 4 HE (coma) because it requires voluntary motor effort. Also seen in uraemia and CO2 retention — not specific to HE.

Covert vs Overt HE

Covert HE = MHE + Grade 1 — no obvious clinical signs, needs psychometric testing (Number Connection Test, Critical Flicker Frequency)
Overt HE = Grade 2–4 — clinically apparent, requires hospitalisation
MHE affects ~30–40% of cirrhotic patients — significant QoL impact, driving impairment, fall risk
MHE detected by Number Connection Test A/B or Digit Symbol Test (available in most hepatology outpatient settings)

Classification by Time Course

Episodic HE: Single acute episode with identifiable precipitant
Recurrent HE: Two or more overt episodes within 6 months — candidates for rifaximin secondary prevention
Persistent HE: Behavioural alterations always present, baseline cognitive impairment — common in advanced cirrhosis
Spontaneous HE: No identifiable precipitant — suggests significant portosystemic shunting or large TIPS

Precipitating Factors — Search Systematically

Increased Ammonia Load

GI bleeding — haemoglobin breakdown produces massive ammonia load
High dietary protein excess
Constipation — prolonged gut transit increases absorption
Portosystemic shunts / TIPS

Infection / Inflammation

SBP (Spontaneous Bacterial Peritonitis) — most important
UTI, pneumonia, cellulitis
Any sepsis — inflammatory mediators synergise with ammonia

Metabolic / Drug

Dehydration — over-diuresis (furosemide/spironolactone), vomiting, diarrhoea
Renal failure / AKI — reduces ammonia excretion
Hypokalaemia — promotes renal ammoniagenesis
Hepatotoxic drugs, benzodiazepines, opioids
HCC progression

TIPS Procedure Warning: Transjugular Intrahepatic Portosystemic Shunt (TIPS) significantly increases HE risk by diverting portal blood (ammonia-rich) away from the liver. Post-TIPS patients require close monitoring for new or worsening HE. Rifaximin is routinely considered as prophylaxis post-TIPS.

Clinical Assessment & Monitoring

Daily structured neurological assessment with documented HE grading is essential for transplant listing decisions and tracking treatment response. Use the same assessment tool consistently between nurses.

Neurological Assessment — Step by Step

AVPU / GCS

Alert → Voice response → Pain response → Unresponsive. GCS for ICU/ALF. Record best motor, verbal, eye response separately.

Orientation (Time / Place / Person)

Ask: current day, month, year, current location, their full name. Grade 1 = confused to time; Grade 2 = confused to place; Grade 3 = disoriented to person.

Asterixis Assessment

Ask patient to hold arms outstretched, wrists maximally dorsiflexed, eyes closed — for 15–30 seconds. Positive = involuntary rhythmic flexion–extension flap. Grade: absent / mild–intermittent / persistent.

Speech & Cognition

Normal → slurred → disorganised → absent. Simple tasks: count backwards 20→1, name months in reverse.

Pupil Assessment

In Grade 3–4: check pupils. Fixed and dilated = herniation / coning — EMERGENCY. Asymmetric pupils = space-occupying lesion until proven otherwise.

Ammonia Testing — Key Points

Venous ammonia preferred — arterial not routinely required; false elevations from arterial sampling technique
Tourniquet-free venepuncture — tourniquet causes local muscle ischaemia → false elevation
Process within 15 minutes of collection — on ice, no delay; ammonia is unstable at room temperature
Normal: <60 μmol/L — correlates loosely with grade but individual variation significant
Very high ammonia (>150–200 μmol/L) in ALF associated with raised ICP and cerebral herniation risk
Serial trending more useful than single value — consistent rise signals deterioration
Normal ammonia does not exclude HE — neuroinflammation can drive HE independently

⚠

Communicate to lab: "venous ammonia — no tourniquet, process immediately." Document collection conditions in notes.

Critically Ill Patients — Advanced Monitoring

Intracranial Pressure Monitoring (ICP): Invasive (epidural/subdural bolt or intraparenchymal device) — reserved for ALF Grade 3–4 patients listed for liver transplantation; coagulopathy increases placement risk
Target ICP <20–25 mmHg; Cerebral Perfusion Pressure (CPP) >60 mmHg
CT/MRI Head: Mandatory before attributing coma to HE — exclude subdural haematoma (common in coagulopathic patients post-falls), intracerebral bleed, stroke, cerebral oedema
EEG: Triphasic waves suggest HE; exclude non-convulsive status epilepticus in obtunded patients
Transcranial Doppler: Non-invasive ICP trend estimation in some centres

Psychometric Testing (MHE / Covert HE)

Number Connection Test A (NCT-A): Connect numbers 1–25 in order; time >30–45 seconds = abnormal. Simple, low literacy requirement.
Number Connection Test B: Alternates numbers and letters (1-A-2-B-...); more sensitive
Digit Symbol Test: Match symbols to numbers; sensitive to psychomotor speed
Critical Flicker Frequency: Retinal flicker threshold correlates with cortical function in HE
Inhibitory Control Test (ICT): Computer-based; PHES (Psychometric Hepatic Encephalopathy Score) is gold-standard research tool
MHE detected only by these tests — normal bedside exam does not exclude covert HE

Nursing Safety Actions by Grade

HE Grade	Safety Interventions	Monitoring Frequency	Escalation
MHE / Grade 1	Falls risk assessment, no driving advice, medication reconciliation	4–6 hourly neuro obs	Alert medical team to precipitants
Grade 2	Bed rails up (all 4), fall mat, remove hazards, aspiration precautions, NG tube if poor oral intake	2 hourly neuro obs, 2–4 hourly BM	Senior nurse + medical review, HDU consider
Grade 3	Bed rails up, airway adjunct at bedside (Guedel), suction equipment, nil by mouth, urinary catheter	Hourly GCS, continuous SpO2/cardiac monitoring	ICU referral, anaesthetics alert for airway
Grade 4	Secure airway (intubation likely), ICP monitoring in ALF, strict fluid balance, pressure area care	Continuous ICU monitoring	Liver transplant team notification, ICU care

MELD Score & Transplant Monitoring

MELD Score Components

Bilirubin (μmol/L → convert to mg/dL for formula)
INR — prothrombin time
Creatinine (mg/dL)
Formula: 3.78×ln(Bili) + 11.2×ln(INR) + 9.57×ln(Cr) + 6.43
MELD ≥15 = mortality benefit from transplantation
MELD-Na includes sodium — better predictor of 90-day mortality in ACLF

GCC Context — Aetiology

MASLD cirrhosis (Metabolic-Associated Steatotic Liver Disease) — most common underlying cause of HE in GCC driven by metabolic syndrome epidemic (T2DM, obesity, dyslipidaemia)
Hepatitis B and C — decreasing with vaccination and antivirals
Autoimmune hepatitis
Cryptogenic cirrhosis (likely occult MASLD)
Wilson's disease, AIH in younger patients

Management — Ammonia Reduction & Precipitant Treatment

✓

Key Principle: HE treatment = reduce gut ammonia production/absorption + identify and treat the precipitant. Protein restriction is no longer recommended — it worsens sarcopenia and increases ammonia generation from muscle catabolism.

Lactulose — First-Line Treatment

Mechanism of Action

Non-absorbable disaccharide metabolised by colonic bacteria → lactic acid + acetic acid. Acidifies the colon (pH ↓), converting NH3 (diffusible) to NH4+ (ionised, trapped in gut, excreted in stool). Also acts as osmotic laxative — reduces gut transit time and ammonia absorption.

Dosing

Oral / NG: 20–30 mL three to four times daily
Target: 2–3 soft stools per day — titrate dose accordingly
Rectal (if unable to swallow): 200 mL lactulose + 700 mL warm water — retention enema, 20–30 min if possible
Monitor fluid balance — diarrhoea = dehydration = worsened HE

Lactulose Overdose: Excessive diarrhoea → dehydration → electrolyte imbalance (hypokalaemia) → worsens HE. Target is soft stools, NOT diarrhoea. Review and reduce dose if >3 loose stools/day.

Rifaximin — Secondary Prevention

Mechanism of Action

Non-absorbable antibiotic — remains in the gut, modifies gut microbiome composition, reduces ammonia-producing bacteria (Enterobacteriaceae, Clostridia). Does not develop significant resistance.

Indication & Dosing

Dose: 550 mg twice daily (BD) orally
Indication: Secondary prevention of overt HE after the first episode — NICE approved (UK), widely used in GCC
Used in addition to lactulose, not as replacement
55% relative risk reduction in recurrence (RFHE-301 trial)
Also considered post-TIPS and in recurrent HE ≥2 episodes/6 months
Cost — consider in GCC context (generally covered in insurance); generic versions available

Nutritional Management

Protein restriction is OBSOLETE and harmful. Sarcopenia (muscle loss) is an independent predictor of poor outcomes in cirrhosis and worsens HE by reducing ammonia detoxification in muscle.

Protein target: 1.2–1.5 g/kg/day of ideal body weight — maintain even during acute HE
Calorie target: 35–40 kcal/kg/day
Timing: Late evening snack (complex carbohydrate) — reduces overnight fasting-related protein catabolism, proven benefit in cirrhosis
Vegetable/dairy protein preferred over animal/red meat — lower ammoniagenic potential, more fibre
BCAA (Branched-Chain Amino Acids): Isoleucine, leucine, valine supplementation — for patients who cannot tolerate standard protein; helps maintain nitrogen balance without increasing aromatic amino acids (precursors to false neurotransmitters)
NG feeding: Initiate early if Grade 2+ HE prevents adequate oral intake

Adjunct Ammonia-Lowering Therapies

Zinc Supplementation: 25–50 mg elemental zinc three times daily — zinc is an essential cofactor for urea cycle enzymes (carbamoyl phosphate synthetase, ornithine transcarbamylase); deficiency common in cirrhosis
L-Ornithine L-Aspartate (LOLA): Provides substrates for urea cycle and glutamine synthesis in liver/muscle; IV infusion (5 g/hr) or oral granules; evidence strongest in acute overt HE; used in many GCC centres
Sodium Benzoate / Sodium Phenylacetate: Alternative nitrogen scavengers — binds ammonia via alternative pathways (hippurate, phenylacetylglutamine); used mainly in urea cycle disorders but off-label in HE
Probiotics: Emerging evidence — modify gut microbiome, reduce urease-producing bacteria; Lactobacillus / VSL#3; not yet standard of care

Treating Precipitants — Priority Actions

GI Bleeding

Octreotide 50 mcg IV bolus then 50 mcg/hr infusion
IV Terlipressin (varices)
Urgent endoscopy (band ligation / sclerotherapy)
Prophylactic antibiotics (ceftriaxone 1g IV OD × 5 days) — reduces infection + HE risk post-bleed
Lactulose enema to clear blood from gut

Infection (SBP / Sepsis)

Diagnostic paracentesis — PMN >250 cells/mm³ = SBP
IV cefotaxime / pip-tazo as per local protocol
IV albumin 1.5 g/kg day 1, 1 g/kg day 3 — reduces HRS in SBP
Blood cultures, urine culture, CXR, wound swabs
Treat empirically while awaiting cultures

Dehydration / Electrolytes / Drugs

Review and reduce/stop diuretics if dehydrated
IV fluid resuscitation — balanced crystalloid, avoid hypotonic
Correct hypokalaemia (promotes renal ammoniagenesis)
Stop all benzodiazepines, opioids, antihistamines
Constipation: lactulose, micro-enemas
Renal failure: optimise fluid, stop nephrotoxins, AKI pathway

Acute Liver Failure (ALF) — ICU Nursing Management

Definition & Subtypes

Acute Liver Failure (ALF) = coagulopathy (INR ≥ 1.5) + hepatic encephalopathy developing within 26 weeks in a patient without prior liver disease.

HYPERACUTE

Jaundice to encephalopathy < 7 days

Typical aetiology: paracetamol OD, HAV, HEV, ischaemic hepatitis

Best spontaneous survival

ACUTE

Jaundice to encephalopathy 7–28 days

Typical aetiology: HBV, drug-induced liver injury (DILI), Wilson's disease

Intermediate prognosis

SUBACUTE

Jaundice to encephalopathy 29 days – 26 weeks

Typical aetiology: autoimmune hepatitis, seronegative, DILI

Worst spontaneous survival — most need transplant

King's College Criteria (KCC) — Transplant Listing

Paracetamol-Induced ALF

List for transplant if:

pH < 7.3 after adequate resuscitation (24h post-ingestion), OR
All 3 of: INR > 6.5 AND creatinine > 300 μmol/L AND Grade 3–4 HE

Non-Paracetamol ALF

List for transplant if:

INR > 6.5 alone (regardless of other factors), OR
Any 3 of 5 criteria:
- Unfavourable aetiology (drug-induced, seronegative, Wilson's)
- Age < 10 or > 40 years
- Jaundice to HE onset > 7 days (subacute)
- INR > 3.5
- Bilirubin > 300 μmol/L

⚠

KCC has moderate sensitivity for non-paracetamol ALF. Dynamic criteria (MELD, lactate, factor V/factor VIII ratio) may supplement KCC. Document daily INR, creatinine, bilirubin, and HE grade meticulously — this data directly influences transplant listing.

ICU Nursing Priorities in ALF

Raised Intracranial Pressure (ICP)

30° head elevation — semi-recumbent positioning reduces venous congestion; avoid head-down for procedures
Mannitol 0.5–1 g/kg IV — osmotic agent; use for acute ICP crisis; avoid if osmolality >320 mOsm/kg or AKI; may repeat ×1
Hypertonic Saline (3% NaCl): Raise serum Na to 145–155 mmol/L — cerebral vasoconstriction, anti-oedema; now preferred over mannitol in many centres
Induced hypothermia: Target 33–35°C — reduces ammonia production and cerebral metabolic demand; used as bridge to transplantation in refractory ICP; evidence limited
Avoid: Hypercapnia, hypoxia, fever, hypotension, excessive stimulation — all raise ICP
Target ICP <20–25 mmHg, CPP >60 mmHg if ICP monitoring in situ

Coagulopathy Management

Do NOT give FFP/cryoprecipitate prophylactically solely to "correct" INR. ALF produces a balanced coagulopathy (reduced pro- and anti-coagulant factors). Empirical FFP increases thrombosis risk, volume overloads, and removes the INR as a prognostic/listing marker.

Give blood products only for: active bleeding or invasive procedures (ICP monitor insertion, central line, paracentesis)
FFP 10–15 mL/kg pre-procedure (target INR <1.5 for neurosurgical procedures)
Cryoprecipitate for fibrinogen <1.0 g/L
Vitamin K 10 mg IV once — always give to exclude nutritional deficiency as contributor
Platelet transfusion: target >50×10⁹/L pre-procedure
Viscoelastic testing (TEG/ROTEM) more accurate than INR for true bleeding risk

Blood Glucose Management

ALF liver cannot maintain gluconeogenesis/glycogen release → profound hypoglycaemia
4–6 hourly BM monitoring (increase to 1–2 hourly in severe ALF)
10% dextrose infusion: Background infusion 100–150 mL/hr to maintain BG 6–10 mmol/L
Avoid excessive glucose (hyperglycaemia → infection risk, worsened outcome)
Strict glycaemic control: BG 4.4–8 mmol/L in ICU (NICE-SUGAR protocol)
Hypoglycaemia (<4 mmol/L) = 50 mL of 50% dextrose IV and recheck in 15 minutes

Infection Surveillance & Renal Function

ALF patients are profoundly immunocompromised — 80% develop bacterial infection
Daily surveillance cultures: blood, urine, sputum, ascites (if present)
Prophylactic antibiotics: IV ceftriaxone or pip-tazo — many ALF centres start empirically
Antifungal prophylaxis: Fluconazole — Candida infections common, particularly with broad-spectrum antibiotics
AKI (Acute Kidney Injury): Occurs in 40–50% of ALF — multifactorial (haemodynamic, direct toxicity)
CRRT (Continuous Renal Replacement Therapy): Preferred over intermittent HD — haemodynamic stability, ammonia clearance; start early for AKI with fluid overload or electrolyte instability
Avoid nephrotoxins: aminoglycosides, NSAIDs, IV contrast where possible

N-Acetylcysteine (NAC) in ALF

Paracetamol (Acetaminophen) ALF

NAC = standard of care — replenishes hepatic glutathione, prevents NAPQI toxicity
Effective up to 24h post-ingestion (most benefit 0–8h)
IV Protocol: Loading 150 mg/kg over 1h → 50 mg/kg over 4h → 100 mg/kg over 16h (Prescott regime)
Continue beyond standard protocol if INR rising or still encephalopathic
Monitor for anaphylactoid reaction (rash, bronchospasm) — usually during loading dose

Non-Paracetamol ALF

Evidence growing for IV NAC in non-paracetamol ALF (Lee et al., 2009 NEJM) — improved transplant-free survival in Grade 1–2 HE
Used in many GCC and UK liver centres off-label
Mechanism: improves microcirculatory flow, reduces hepatocyte apoptosis, anti-inflammatory
Dose: same IV protocol as paracetamol, continued until LFTs trend down or transplant/death

HE Management in ALF — Specific Points

Lactulose + rifaximin as for cirrhotic HE — titrate lactulose to 2–3 stools/day
Protein: 0.5 g/kg/day initially in Grade 3–4 ALF, increasing to 1.2 g/kg/day as encephalopathy improves — more restrictive than chronic HE due to severity
Sedation: Avoid benzodiazepines — use propofol for intubated patients (short-acting, allows neurological assessment); low-dose haloperidol if agitation requires treatment in non-intubated
Avoid: All hepatotoxic drugs, nephrotoxins, sedatives — medication reconciliation critical
Maintain head of bed at 30°, minimise stimulation

Liver Support Systems & Transplantation

Extracorporeal Liver Support Devices

No extracorporeal liver support device has proven definitive mortality benefit in large RCTs. Current evidence supports use as a bridge to transplantation or spontaneous recovery in selected patients with ALF or acute-on-chronic liver failure (ACLF).

MARS — Molecular Adsorbents Recirculation System

Albumin dialysis — removes protein-bound toxins (bilirubin, bile acids, aromatic amino acids, endogenous benzodiazepines) AND water-soluble toxins (ammonia, creatinine)
Circuit: patient blood → hollow-fibre membrane → albumin circuit → activated charcoal + anion exchanger → regenerated albumin
Improves HE grade, haemodynamics, and renal function in ACLF
Sessions: typically 6–8 hours, daily or on alternate days
Requires ICU setting, specialist nurses trained in circuit management
RELIEF trial (ACLF): improved HE and haemodynamics; HELIOS trial: MARS vs standard medical therapy in ACLF

PROMETHEUS & Other Systems

PROMETHEUS (FPSA): Fractionated Plasma Separation and Adsorption — separates plasma, adsorbs protein-bound toxins, returns; no exogenous albumin required
ELAD (Extracorporeal Liver Assist Device): Bioartificial — human hepatoma cells (C3A line) in cartridges; provides some synthetic function; Phase III (VTI-208 trial) failed primary endpoint
Large Volume Plasma Exchange (LVP): 8–12 L plasma exchange — ASOS trial (ALF): significantly improved transplant-free survival; low-cost alternative; growing evidence base
Available in selected GCC transplant centres (King Faisal Hospital, Cleveland Clinic Abu Dhabi, Hamad Medical Corporation)

Liver Transplantation

Super-Urgent Listing (Deceased Donor)

KCC met → immediate listing on super-urgent (SU) register
Waiting list mortality in ALF is high — hours to days, not months
ABO-compatible grafts; time-critical — accept extended criteria donors
Pre-transplant: optimise haemodynamics, treat infection, continue ICU support
Contraindications: uncontrolled sepsis (relative), multiple organ failure, psychiatric/psychosocial criteria (substance misuse — some centres require abstinence period)

Living Donor Liver Transplant (LDLT)

Compatible relative may donate right lobe — avoids deceased donor wait
LDLT highly developed in GCC (KSA, UAE, Qatar) — cultural preference for family donation
Right lobe hepatectomy carries ~0.5% donor mortality risk — requires full informed consent
Rapid workup (3–5 days): ABO compatibility, CT volumetry, liver biopsy, psychosocial clearance
Graft survival comparable to deceased donor transplant

Pre- and Post-Transplant Nursing

Pre-transplant viral prophylaxis: Entecavir or tenofovir for HBV — prevent post-transplant recurrence
Nutritional optimisation — TPN if gut not functioning
Psychological support — patient and family
Consent discussion involvement — living donor cases

Post-transplant immunosuppression: Triple therapy — tacrolimus (CNI) + mycophenolate mofetil (MMF) + prednisolone
Monitor tacrolimus levels (trough 8–12 ng/mL early post-transplant)
HE typically resolves post-transplant (days to weeks)
Watch for: rejection, infection, CNI nephrotoxicity, metabolic complications

Palliative Care in Liver Disease

When transplant is not an option — unacceptable surgical risk (multi-organ failure, severe cardiac disease), psychosocial contraindications, patient refusal, or no available graft
Symptom management priorities: HE (lactulose/rifaximin ongoing), ascites (diuretics, regular large-volume paracentesis), pain (avoid opioids/NSAIDs where possible — fentanyl patches cautiously), pruritus (cholestyramine, rifampicin)
Refractory ascites: TIPSS if not contraindicated; tunnelled peritoneal drain; automated low-flow ascites pump (Alfapump)
Prognosis communication: MELD score translates to 90-day mortality probability; involve family with patient's consent; GCC cultural considerations — family-centred decision making, involvement of patient's designated spokesperson
Advance Care Planning: Document resuscitation status, ceiling of care, ICU escalation wishes; involve chaplaincy/spiritual care as appropriate
Multidisciplinary team: hepatologist, palliative care, social work, dietitian, pharmacist

GCC Context & Clinical Exam Preparation

GCC-Specific Hepatology Context

Aetiology of ALF in GCC

Paracetamol (Acetaminophen) OD: Less common than UK/USA — lower rates of intentional self-harm in GCC (cultural, religious factors); however, inadvertent therapeutic overdose occurs (combination products, chronic daily use)
Herbal and traditional medicines: Very common in GCC — khat, Teucrium (germander), traditional Arabic herbal remedies, black seed oil in excess — cause DILI and ALF; always ask in drug history
Isoniazid (INH): TB prophylaxis and treatment widely used in GCC due to expat TB burden — drug-induced hepatitis, ALF; monitor LFTs monthly when on INH
HBV: Prevalence varies — higher in expat workers from endemic regions; vaccination programmes have reduced rates

Cirrhosis & HE Aetiology in GCC

MASLD (Metabolic-Associated Steatotic Liver Disease) — fastest growing aetiology of cirrhosis in GCC; driven by high rates of T2DM (~20% in UAE, KSA), obesity, dyslipidaemia, sedentary lifestyle
MASLD → MASH → cirrhosis → decompensation with HE is the dominant clinical pathway in GCC hepatology wards
Cryptogenic cirrhosis — likely underlying MASLD in most cases
Haemochromatosis and alpha-1 antitrypsin deficiency — less common but seen
GCC nursing staff must know common herbal remedies used in their patient population — communicate without judgement, screen all admissions

Regulatory Bodies & Exam Focus

DHA (Dubai Health Authority)

HE classification (WHC grades)
Lactulose mechanism and dose titration
Ammonia sample handling
Patient safety in Grade 3–4 HE

DOH (Department of Health Abu Dhabi)

ALF definition and KCC
NAC administration and monitoring
Nutritional management in cirrhosis
TIPS complications including HE

SCFHS (Saudi Commission)

West Haven Criteria application
Rifaximin indications
ICP management in ALF
Transplant listing criteria

HE Grade Assessor — Clinical Decision Tool

Rate each clinical parameter to receive West Haven Grade, nursing safety interventions, ammonia urgency, lactulose recommendation, and escalation pathway.

Orientation

Asterixis (Flapping Tremor)

Sleep Disturbance

Speech

Motor Response

Safety Interventions

Ammonia Testing

Lactulose

Escalation

Practice MCQs — DHA / DOH / SCFHS Style

Hepatic Encephalopathy & Acute Liver Failure Nursing